ALS Limited reports financial results

ALS (ASX:ALQ), a leader in the Testing, Inspection, and Certification industry, has announced its financial results for the first half of fiscal year 2025 ending 30 September 2024. The company achieved a 14% increase in revenue, totaling AUD 1,464.2 million, despite facing foreign exchange challenges. ALS maintained solid margins through its diversified business model and strategic acquisitions.

ALS's strategic outlook and future plans

ALS Limited has shown resilience in its H1 FY25 results, navigating mixed market conditions and foreign exchange impacts. The company reported a 14% rise in revenue, with notable performance in its Life Sciences segment, driven by organic growth and strategic acquisitions. ALS aims for mid-single digit organic growth for the fiscal year 2025, focusing on operational improvements and strategic capital allocation. The company is also working on integrating recent acquisitions to enhance margin contributions and expand its global reach, particularly in Environmental and Pharmaceutical testing. ALS maintains a strong commitment to health, safety, and sustainability, and plans to reduce leverage in the coming months through disciplined capital management.

Executive insights on ALS's performance

The first half results reflect our strategic focus on diversifying our business model and integrating recent acquisitions, despite facing FX headwinds. We remain committed to leveraging industry megatrends and optimizing our global platform to drive sustainable growth,' stated the ALS executive team.